190 related articles for article (PubMed ID: 37833892)
1. Long-Term Evaluation of Biomarkers in the Czech Cohort of Gaucher Patients.
Malinová V; Poupětová H; Řeboun M; Dvořáková L; Reichmannová S; Švandová I; Murgašová L; Kasper DC; Magner M
Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37833892
[TBL] [Abstract][Full Text] [Related]
2. Glucosylsphingosine (Lyso-Gb
Gayed MM; Jung SH; Huggins E; Rodriguez-Rassi E; DeArmey S; Kishnani PS; Stiles AR
Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36499264
[TBL] [Abstract][Full Text] [Related]
3. Glucosylsphingosine is a key biomarker of Gaucher disease.
Murugesan V; Chuang WL; Liu J; Lischuk A; Kacena K; Lin H; Pastores GM; Yang R; Keutzer J; Zhang K; Mistry PK
Am J Hematol; 2016 Nov; 91(11):1082-1089. PubMed ID: 27441734
[TBL] [Abstract][Full Text] [Related]
4. A Brazilian Rare-Disease Center's Experience with Glucosylsphingosine (lyso-Gb1) in Patients with Gaucher Disease: Exploring a Novel Correlation with IgG Levels in Plasma and a Biomarker Measurement in CSF.
Vernet Machado Bressan Wilke M; Iop GD; Faqueti L; Lemos da Silva LA; Kubaski F; Poswar FO; Michelin-Tirelli K; Randon D; Borelli WV; Giugliani R; Schwartz IVD
Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474117
[TBL] [Abstract][Full Text] [Related]
5. An observational study to investigate the relationship between plasma glucosylsphingosine (lyso-Gb1) concentration and treatment outcomes of patients with Gaucher disease in Japan.
Ida H; Watanabe Y; Sagara R; Inoue Y; Fernandez J
Orphanet J Rare Dis; 2022 Nov; 17(1):401. PubMed ID: 36329499
[TBL] [Abstract][Full Text] [Related]
6. Reductions in glucosylsphingosine (lyso-Gb1) in treatment-naïve and previously treated patients receiving velaglucerase alfa for type 1 Gaucher disease: Data from phase 3 clinical trials.
Elstein D; Mellgard B; Dinh Q; Lan L; Qiu Y; Cozma C; Eichler S; Böttcher T; Zimran A
Mol Genet Metab; 2017 Sep; 122(1-2):113-120. PubMed ID: 28851512
[TBL] [Abstract][Full Text] [Related]
7. Glucosylsphingosine (lyso-Gb1) as a Biomarker for Monitoring Treated and Untreated Children with Gaucher Disease.
Hurvitz N; Dinur T; Becker-Cohen M; Cozma C; Hovakimyan M; Oppermann S; Demuth L; Rolfs A; Abramov A; Zimran A; Revel-Vilk S
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234327
[TBL] [Abstract][Full Text] [Related]
8. Contribution of Glucosylsphingosine (Lyso-Gb1) to Treatment Decisions in Patients with Gaucher Disease.
Dinur T; Bauer P; Beetz C; Cozma C; Becker-Cohen M; Istaiti M; Rolfs A; Skrahina V; Zimran A; Revel-Vilk S
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835356
[TBL] [Abstract][Full Text] [Related]
9. Impact of Long-Term Enzyme Replacement Therapy on Glucosylsphingosine (Lyso-Gb1) Values in Patients with Type 1 Gaucher Disease: Statistical Models for Comparing Three Enzymatic Formulations.
Dinur T; Grittner U; Revel-Vilk S; Becker-Cohen M; Istaiti M; Cozma C; Rolfs A; Zimran A
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299318
[TBL] [Abstract][Full Text] [Related]
10. Treatment Efficiency in Gaucher Patients Can Reliably Be Monitored by Quantification of Lyso-Gb1 Concentrations in Dried Blood Spots.
Cozma C; Cullufi P; Kramp G; Hovakimyan M; Velmishi V; Gjikopulli A; Tomori S; Fischer S; Oppermann S; Grittner U; Bauer P; Beetz C; Rolfs A
Int J Mol Sci; 2020 Jun; 21(13):. PubMed ID: 32605119
[TBL] [Abstract][Full Text] [Related]
11. Glucosylsphingosine (Lyso-Gb1) as a reliable biomarker in Gaucher disease: a narrative review.
Giuffrida G; Markovic U; Condorelli A; Calafiore V; Nicolosi D; Calagna M; Grasso S; Ragusa MTV; Gentile J; Napolitano M
Orphanet J Rare Dis; 2023 Feb; 18(1):27. PubMed ID: 36782327
[TBL] [Abstract][Full Text] [Related]
12. Value of Glucosylsphingosine (Lyso-Gb1) as a Biomarker in Gaucher Disease: A Systematic Literature Review.
Revel-Vilk S; Fuller M; Zimran A
Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32998334
[TBL] [Abstract][Full Text] [Related]
13. Detection of glucosylsphingosine in dried blood spots for diagnosis of Gaucher disease by LC-MS/MS.
Tang C; Jia X; Tang F; Liu S; Jiang X; Zhao X; Sheng H; Peng M; Liu L; Huang Y
Clin Biochem; 2021 Jan; 87():79-84. PubMed ID: 33188770
[TBL] [Abstract][Full Text] [Related]
14. High-Dose Ambroxol Therapy in Type 1 Gaucher Disease Focusing on Patients with Poor Response to Enzyme Replacement Therapy or Substrate Reduction Therapy.
Istaiti M; Frydman D; Dinur T; Szer J; Revel-Vilk S; Zimran A
Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047707
[TBL] [Abstract][Full Text] [Related]
15. Insights into the Value of Lyso-Gb1 as a Predictive Biomarker in Treatment-Naïve Patients with Gaucher Disease Type 1 in the LYSO-PROOF Study.
Curado F; Rösner S; Zielke S; Westphal G; Grittner U; Skrahina V; Alasel M; Malik AM; Beetz C; Böttcher T; Barel G; Sah AP; Dinur T; Anjum N; Ichraf Q; Kriouile Y; Hadipour Z; Hadipour F; Revel-Vilk S; Cozma C; Hartkamp J; Cheema H; Zimran A; Bauer P; Rolfs A;
Diagnostics (Basel); 2023 Aug; 13(17):. PubMed ID: 37685353
[TBL] [Abstract][Full Text] [Related]
16. Value of plasma chitotriosidase to assess non-neuronopathic Gaucher disease severity and progression in the era of enzyme replacement therapy.
van Dussen L; Hendriks EJ; Groener JE; Boot RG; Hollak CE; Aerts JM
J Inherit Metab Dis; 2014 Nov; 37(6):991-1001. PubMed ID: 24831585
[TBL] [Abstract][Full Text] [Related]
17. Metabolomic Study Using Time-of-Flight Mass Spectrometry Reveals Novel Urinary Biomarkers for Gaucher Disease Type 1.
Menkovic I; Boutin M; Alayoubi A; Curado F; Bauer P; Mercier FE; Auray-Blais C
J Proteome Res; 2022 May; 21(5):1321-1329. PubMed ID: 35349295
[TBL] [Abstract][Full Text] [Related]
18. Gaucher Disease Diagnosis Using Lyso-Gb1 on Dry Blood Spot Samples: Time to Change the Paradigm?
Dinur T; Bauer P; Beetz C; Kramp G; Cozma C; Iurașcu MI; Becker-Cohen M; Istaiti M; Rolfs A; Zimran A; Revel-Vilk S
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163551
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive and long-term outcomes of enzyme replacement therapy followed by stem cell transplantation in children with Gaucher disease type 1 and 3.
Anurathapan U; Tim-Aroon T; Zhang W; Sanpote W; Wongrungsri S; Khunin N; Chutipongtanate S; Chirdkiatgumchai V; Ngiwsara L; Jaovisidha S; Khongkraparn A; Pakakasama S; Svasti J; Setchell KDR; Wattanasirichaigoon D; Hongeng S
Pediatr Blood Cancer; 2023 Mar; 70(3):e30149. PubMed ID: 36562549
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of eliglustat combined to enzyme replacement therapy for lymphadenopathy in patients with Gaucher disease type 3.
Lee NC; Chien YH; Wang CH; Wong SL; Peng SS; Tsai FJ; Hwu WL
Mol Genet Metab Rep; 2022 Jun; 31():100867. PubMed ID: 35782609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
